ketanserin has been researched along with Cognition Disorders in 1 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Svarer, C | 1 |
| Madsen, K | 1 |
| Hasselbalch, SG | 1 |
| Pinborg, LH | 1 |
| Haugbøl, S | 1 |
| Frøkjaer, VG | 1 |
| Holm, S | 1 |
| Paulson, OB | 1 |
| Knudsen, GM | 1 |
1 trial available for ketanserin and Cognition Disorders
| Article | Year |
|---|---|
MR-based automatic delineation of volumes of interest in human brain PET images using probability maps.
Topics: Aged; Aged, 80 and over; Aging; Algorithms; Atrophy; Brain; Brain Mapping; Cognition Disorders; Fema | 2005 |